Release Date: 08-Feb-2023
The advancements in science and consequently, the treatment approaches, have significantly encouraged the growth and adoption of more modern therapies like immunotherapy. Monoclonal antibodies are one of the most successful forms of immunotherapy that has laid the foundation for the development of multispecific antibodies. Since the last decade, bispecific antibodies have been rapidly gaining popularity and have made their way into clinical trials, and many of these have gained market approvals as well. The numerous benefits that bispecific antibodies have demonstrated in clinical and preclinical studies have led to a newly generated interest in the biopharma field globally and the trend is expected to continue as more candidates get approved for real-time use.
Download Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028:
Till now, quite a few bispecific antibodies have been approved by drug regulatory bodies around the world for commercial use out of which Blincyto and Hemlibra have generated the majority of revenue since their approvals. Without a doubt, these two are greatly responsible for the growing interest in the therapeutic potential of bispecific antibodies. The focus on bispecific antibodies has gained momentum in the recent years, leading to an exponential growth in the total number of drugs in clinical development, some of which are slowly seeping into the market for commercial use. As per our research, over eight antibodies have been granted approval and most of these are being used in the treatment of cancer, though indications also include hereditary, autoimmune and inflammatory diseases.
This newfound interest in bispecific antibodies has also caused a surge in partnerships and collaborations in the global pharmaceutical market. Such collaborations allow the concerned parties to make use of each other’s resources, which helps in cost cutting and access to the newest technologies. For instance, Alligator Biosciences recently announced the expansion of its research collaboration and license agreement with Orion Corp to discover and develop new bispecific antibodies for treating cancer. Alligator Biosciences will use its proprietary bispecific RUBY platform to provide validated monospecific binders for one target and Orion will do the same for other target. With both companies complementing each other’s scientific expertise, the collaborative agreement is one to look to. Previously, Alligator had also entered agreements with Aptevo and Biotheus for its other bispecific candidates.
As the pipelines are expanding, a few candidates are getting closer to getting approvals. Glofitamab, an investigational CD20xCD3 T cell engaging bispecific antibody developed by Genentech (Roche), had its Biologics License application accepted by the US FDA in January 2023. Along with this, it was also granted the Priority review for the treatment of patients with relapsed or refractory large B-cell lymphoma. If it gets approved, it would be the first fixed-duration, off-the-shelf CD20xCD3 T cell engaging bispecific antibody. The BLA is based on data from phase I/II NP30179 study which showed that Glofitamab induced durable response rates in people with heavily pretreated large B cell lymphoma, with 40% achieving a complete response.
The onset of bispecific antibodies has boosted the landscape of cancer treatment and simultaneously also boosted the cancer therapeutics market. The rising incidences of cancer and the unavailability of effective drugs have generated an unmet need for which development of novel targeted cancer therapies like bispecific antibodies has become a must. With improving technologies, prominent pharmaceutical giants are actively investing in research and development activities for bispecific antibodies, which have led to the creation of candidates against various diseases apart from cancer. Thus, the global bispecific antibody market is anticipated to grow exponentially in the coming years because the pipelines for this modality are very robust. When compared to conventional therapies, bispecific antibodies have shown enhanced efficacy and ease in manufacturation due to their small size.
The report aims to provide an in-depth analysis on the current market growth for bispecific antibodies and will also provide input on the future outlook this therapy will have on the market. The market analysis is done on regions basis, with insights on patents, dosage, price and sales analysis of the currently existing commercially available bispecific antibodies. As of now, the US holds the major share in the global bispecific antibody market with several factors attributing to its growth. Our report highlights the current situation in the industry, sharing knowledge on the ongoing clinical trials for bispecific antibodies and the key market players.